Monika Mannan, MD
Endocrinology, Diabetes & Metabolism · Rockville, MDNPI 1558472498
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,379 of the $8,229 with a category attached, or 89.7%. It is spread thinly across 38 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,573, 2.6 times the $994 reported in 2019.
Across 205 payments — averaging $40.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Medtronic$1K
- Lilly USA, LLC$828
- Dexcom, Inc.$621
- Corcept Therapeutics$585
- AstraZeneca$581
- plus $3K from 32 others
What the payments were for
- Travel & lodging$6578%
- Food & beverage$7,37990%
- Education$741%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $1,156 |
| Medtronic(2 entities) | 16 | $1,103 |
| Lilly USA, LLC | 39 | $828 |
| Dexcom, Inc. | 6 | $621 |
| Corcept Therapeutics | 11 | $585 |
| AstraZeneca(2 entities) | 7 | $581 |
| Bayer | 12 | $459 |
| AbbVie | 6 | $301 |
| Insulet Corporation | 7 | $263 |
| Amgen(2 entities) | 4 | $255 |
| Madrigal Pharmaceuticals | 4 | $218 |
| Amneal Pharmaceuticals LLC | 12 | $197 |
| Mannkind Corporation | 6 | $194 |
| Sanofi-aventis U.S. LLC | 5 | $165 |
| Echosens North America, Inc. | 1 | $160 |
| Xeris Pharmaceuticals, Inc. | 9 | $153 |
| GSK | 1 | $125 |
| Tandem Diabetes Care, Inc. | 3 | $120 |
| BETA Bionics, Inc. | 1 | $102 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Recordati_rare_diseases_inc. | 3 | $61 |
| Amarin Pharma, Inc. | 3 | $59 |
| Pfizer | 2 | $56 |
| Sequel Med Tech, LLC | 2 | $53 |
| Boehringer Ingelheim | 2 | $49 |
| Acella Pharmaceuticals, LLC | 2 | $42 |
| Abbott | 2 | $29 |
| Alfasigma USA, Inc. | 1 | $25 |
| Soleno Therapeutics, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Antares Pharma, Inc. | 1 | $23 |
| Nevro Corp. | 1 | $23 |
| Shire North American Group Inc | 1 | $18 |
| Lifescan, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$653
- Korlym$455
- Kerendia$351
- iLet Bionic Pancreas$305
- DEXCOM G6 TRANSMITTER$252
- UBRELVY$246
- Wegovy$242
- FARXIGA$242
- Ozempic$221
- DEXCOM G7 GSS (161)$216
- FibroScan$160
- Omnipod$152
- REZDIFFRA$143
- DEXCOM CGM$127
- AREXVY$125
- TEPEZZA$125
- QULIPTA$121
- DEXCOM STELO GLUCOSE BIOSENSOR$115
- Tresiba$104
- iLet Insulin Infusion Kit Inset$102
How this compares
$8,229 in reported general payments places this provider in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 323 | $595,117 |
| MounjaroTirzepatide | 141 | $217,036 |
| JardianceEmpagliflozin | 143 | $202,004 |
| TrulicityDulaglutide | 118 | $180,803 |
| JanuviaSitagliptin Phosphate | 88 | $105,243 |
| FarxigaDapagliflozin Propanediol | 68 | $95,487 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 138 | $69,310 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 35 | $61,714 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 50 | $47,485 |
| TradjentaLinagliptin | 40 | $42,405 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $36,384 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $28,471 |
| FiaspInsulin Aspart (Niacinamide) | 15 | $27,641 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $26,704 |
| Cinacalcet Hcl | 29 | $23,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $1,156 | $629,467361 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $828 | $403,413275 claims |
| Boehringer IngelheimJardiance, Tradjenta | $49 | $244,408183 claims |
| AstraZenecaFarxiga | $581 | $95,48768 claims |
| AbbVieSynthroid | $301 | $11,839113 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $197 | $7,131673 claims |
| Sanofi-aventis U.S. LLCLantus | $165 | $1,69911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Rockville
- David BrownRockville$497K
- Helena RodbardRockville$468K
- Gerti TashkoRockville$106K
- Jie HeRockville$26K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- Philip LevinBaltimore$489K
- Roy PhillipsBel Air$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.